Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

A single center clinical analysis of children with high-risk neuroblastoma.

Tian X, Cao Y, Wang J, Yan J, Tian Y, Li Z, Wang H, Duan X, Jin Y, Zhao Q.

Oncotarget. 2017 May 2;8(18):30357-30368. doi: 10.18632/oncotarget.15996.

2.

Short-Interval Retreatment With Stereotactic Body Radiotherapy (SBRT) for Pediatric Neuroblastoma Resulting in Severe Myositis.

Taunk NK, Kushner B, Ibanez K, Wolden SL.

Pediatr Blood Cancer. 2016 Apr;63(4):731-3. doi: 10.1002/pbc.25863. Epub 2016 Jan 25.

3.

Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.

Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, Roberts SS, Basu EM, Yataghene K, Cheung NK.

Oncotarget. 2016 Jan 26;7(4):4155-66. doi: 10.18632/oncotarget.6393.

4.

Local control in metastatic neuroblastoma in children over 1 year of age.

De Ioris MA, Crocoli A, Contoli B, Garganese MC, Natali G, Tomà P, Jenkner A, Boldrini R, De Pasquale MD, Milano GM, Madafferi S, Castellano A, Locatelli F, Inserra A.

BMC Cancer. 2015 Feb 21;15:79. doi: 10.1186/s12885-015-1082-7.

5.

Osteochondroma in long-term survivors of high-risk neuroblastoma.

Kushner BH, Roberts SS, Friedman DN, Kuk D, Ostrovnaya I, Modak S, Kramer K, Basu EM, Cheung NK.

Cancer. 2015 Jun 15;121(12):2090-6. doi: 10.1002/cncr.29316. Epub 2015 Feb 27.

6.

Outcomes After Radiation Therapy to Metastatic Sites in Patients With Stage 4 Neuroblastoma.

Kandula S, Prabhu RS, Nanda R, Switchenko JM, Cash T, Qayed M, Katzenstein H, Esiashvili N.

J Pediatr Hematol Oncol. 2015 Apr;37(3):175-80. doi: 10.1097/MPH.0000000000000264.

7.

Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.

Kushner BH, Modak S, Kramer K, LaQuaglia MP, Yataghene K, Basu EM, Roberts SS, Cheung NK.

Cancer. 2014 Jul 1;120(13):2050-9. doi: 10.1002/cncr.28687. Epub 2014 Apr 1.

8.

Clinical results of proton beam therapy for advanced neuroblastoma.

Oshiro Y, Mizumoto M, Okumura T, Sugahara S, Fukushima T, Ishikawa H, Nakao T, Hashimoto T, Tsuboi K, Ohkawa H, Kaneko M, Sakurai H.

Radiat Oncol. 2013 Jun 12;8:142. doi: 10.1186/1748-717X-8-142.

9.
10.

A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.

Furman WL, McGregor LM, McCarville MB, Onciu M, Davidoff AM, Kovach S, Hawkins D, McPherson V, Houghton PJ, Billups CA, Wu J, Stewart CF, Santana VM.

Invest New Drugs. 2012 Aug;30(4):1660-70. doi: 10.1007/s10637-011-9724-3. Epub 2011 Jul 28.

11.

Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience.

Robbins JR, Krasin MJ, Pai Panandiker AS, Watkins A, Wu J, Santana VM, Furman WL, Davidoff AM, McGregor LM.

J Pediatr Surg. 2010 Apr;45(4):678-86. doi: 10.1016/j.jpedsurg.2009.11.003.

12.

KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.

Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung IY, Dupont B, O'Reilly RJ, Cheung NK, Hsu KC.

Clin Cancer Res. 2009 Dec 1;15(23):7330-4. doi: 10.1158/1078-0432.CCR-09-1720. Epub 2009 Nov 24.

13.

Locoregional tumor progression after radiation therapy influences overall survival in pediatric patients with neuroblastoma.

Pai Panandiker AS, McGregor L, Krasin MJ, Wu S, Xiong X, Merchant TE.

Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1161-5. doi: 10.1016/j.ijrobp.2009.03.068. Epub 2009 Aug 11.

14.

Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma.

Kushner BH, Kramer K, Modak S, Qin LX, Yataghena K, Jhanwar SC, Cheung NK.

Pediatr Blood Cancer. 2009 Jul;53(1):17-22. doi: 10.1002/pbc.21931.

16.

Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haemopoietic stem cell transplantation to consolidate primary treatment.

Luksch R, Podda M, Gandola L, Polastri D, Piva L, Castellani R, Collini P, Massimino M, Cefalo G, Terenziani M, Ferrari A, Casanova M, Spreafico F, Meazza C, Bozzi F, Marchianò A, Ravagnani F, Fossati-Bellani F.

Br J Cancer. 2005 Jun 6;92(11):1984-8.

17.

Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis.

Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, Harris AL; Tumour and Angiogenesis Research Group.

Br J Cancer. 2003 Sep 1;89(5):877-85.

Supplemental Content

Support Center